Apic Bio Announces $40M Series A Financing to Advance Novel Gene Therapies for Rare Genetic Disorders
Search for cure against the lethal disease ALS boosted by new investor
Search for cure against the lethal disease ALS boosted by new investor
Orphazyme closes a €14 million Series B Extension
Orphazyme closes a €14 million Series B Extension
Amylyx Pharmaceuticals Receives FDA Orphan Drug Designation for AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis
Amylyx Pharmaceuticals Receives FDA Orphan Drug Designation for AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis
Project ALS and Amylyx Enter Collaboration to Test AMX0035
Project ALS and Amylyx Enter Collaboration to Test AMX0035
Amylyx closes a $ 5 million Series A Investment
Amylyx closes a $ 5 million Series A Investment
Amylyx Pharmaceuticals Doses First Patient in Phase II Clinical Trial of AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis
Amylyx Pharmaceuticals Doses First Patient in Phase II Clinical Trial of AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis
Verge Genomics
Verge Genomics announces $32 Million Series A to Lead Artificial Intelligence-Driven Drug Discovery
Orphazyme, joint portfolio company of ALS Investment Fund and LSP, raises approximately €80 million in oversubscribed IPO
Orphazyme, joint portfolio company of ALS Investment Fund and LSP, raises approximately €80 million in oversubscribed IPO